Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 720975, 6 pages
http://dx.doi.org/10.1155/2013/720975
Research Article

CXCR1/CXCR2 Antagonism Is Effective in Pulmonary Defense against Klebsiella pneumoniae Infection

1Department of Immunology, Dalian Medical University, Dalian 116044, China
2Department of Clinical Laboratory, Karamay Central Hospital, Karamay 834000, China
3Department of Biochemistry, Dalian Medical University, Dalian 116044, China
4Department of Life Science, Institute of Biotechnology, National Tsing Hua University, Hsinchu 300, Taiwan
5The Division of Respirology, Critical Care and Sleep Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada S7N 0W8

Received 13 July 2012; Revised 14 January 2013; Accepted 25 January 2013

Academic Editor: Jozef Anné

Copyright © 2013 Jing Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Klebsiella pneumoniae-associated pathology is largely mediated by neutrophilic inflammation. In this study, we administered Klebsiella pneumoniae to experimental guinea pig groups and the ELR-CXC chemokine antagonist , ceftazidime, and dexamethasone to different groups, respectively. After 24 h, we assessed the animal’s pulmonary inflammatory levels, including gross histopathology, airway neutrophilia, lung myeloperoxidase levels, expressions of CXCL8 and TNF, and airway bacterial loads. Compared with ceftazidime and dexamethasone treatments, the administration of the ELR-CXC chemokine antagonist alone was more effective than other methods, although it did not markedly attenuate the bacterial load. These results suggest new methods for the treatment of Klebsiella pneumoniae pathology.